Berobenatide once a week compared with placebo for adults with obesity in Japan
Tests weekly berobenatide against placebo in Japanese adults with obesity.
Plain-language title generated from the registry record
Registry title: A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)
Key facts
- Where
- Amagasaki, Chiyoda-ku, Chuo-ku, Fukuoka, Hachiōji, Hachioji-shi, Kasuya-gun, Matsuyama, Mihama-ku, Minato-ku, Minoh, Mito, Naka, Nerima-ku, Osaka-shi Ikuno-ku, Sapporo, Shinjuku-ku, Soka-shi, Suita, Takamatsu, Tokyo, Toshima-ku, Toyonaka-shi, and Yokohama, JapanSee the 36 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in Japan with obesity disease who also have related health problems. Some may also have type 2 diabetes.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- BMI of 27.0 kg/m2 to under 35.0 kg/m2 with at least 2 obesity-related health disorders, or BMI of 35.0 kg/m2 or more with at least 1. At least one disorder must be high blood pressure, abnormal blood fats (dyslipidemia) or glucose intolerance (type 2 diabetes, impaired glucose tolerance and similar).
Main reasons for not taking part
- Body weight changed by more than 5% in the 90 days before screening
- Type 1 diabetes or any form of diabetes other than type 2
- History of acute or chronic pancreatitis
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2)
Read by machine on 9 November 2026.
Where in Japan
- Yamasaki Family ClinicAmagasaki, JapanTaking people
- Doujin Memorial Foundation, Meiwa HospitalChiyoda-ku, JapanTaking people
- AIC Yaesu ClinicChuo-ku, JapanTaking people
- Fukuwa ClinicChuo-ku, JapanTaking people
- Tokyo Asbo ClinicChuo-ku, JapanTaking people
- Tokyo Center ClinicChuo-ku, JapanTaking people
- Tokyo-Eki Center-building ClinicChuo-ku, JapanTaking people
- Fukuoka Diagnostic Imaging Clinic Me-WellFukuoka, JapanTaking people
- Medical Corporation Boocs Boocs Clinic FukuokaFukuoka, JapanTaking people
- Tenjin Sogo ClinicFukuoka, JapanTaking people
- Keikokai Medical Corporation P-one ClinicHachiōji, JapanTaking people
- Hachioji Clinic ShinchoHachioji-shi, JapanTaking people
- Medical Corp Seikoukai New Medical Research System ClinicHachioji-shi, JapanTaking people
- Oishi ClinicKasuya-gun, JapanTaking people
- Matsuyama Shimin HospitalMatsuyama, JapanTaking people
- Mikannohana Clinic, Diabetes, Endocrinology and MetabolismMatsuyama, JapanTaking people
- Tokuyama ClinicMihama-ku, JapanTaking people
- Patient First Clinic Ginza-ShimbashiMinato-ku, JapanTaking people
- Yokoi ClinicMinoh, JapanTaking people
- Minami Akatsuka ClinicMito, JapanTaking people
- Mito Saiseikai General HospitalMito, JapanTaking people
- Nishiyamado Keiwa HospitalNaka, JapanTaking people
- Shimamura Memorial HospitalNerima-ku, JapanTaking people
- Kanemura ClinicOsaka-shi Ikuno-ku, JapanTaking people
- Manda Memorial HospitalSapporo, JapanTaking people
- Higashi-Shinjuku Clinic, Keikokai Medical Corp.Shinjuku-ku, JapanTaking people
- Medical Corporation Heishinkai ToCROM ClinicShinjuku-ku, JapanTaking people
- Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical CorporationShinjuku-ku, JapanTaking people
- Saiyu Soka HospitalSoka-shi, JapanTaking people
- Soka Sugiura Internal medicine ClinicSoka-shi, JapanTaking people
- Medical Corporation Heishinkai OCROM ClinicSuita, JapanTaking people
- Olive Takamatsu Medical ClinicTakamatsu, JapanTaking people
- Nihonbashi Sakura ClinicTokyo, JapanTaking people
- Ikebukuro Metropolitan ClinicToshima-ku, JapanTaking people
- MI Clinic, Medical Corporation JinsenkaiToyonaka-shi, JapanTaking people
- Medical Corporation Hitomikai Motomachi Takatsuka Naika ClinicYokohama, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Pfizer
- Trial code
- NCT07794761
- Record updated
- 5 November 2026
- Original description
The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition where a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some people in this study may also have type 2 diabetes, a condition in which the body does not use insulin properly, causing blood sugar levels to become too high.Read full original descriptionShow less
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JW)
The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition where a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some people in this study may also have type 2 diabetes, a condition in which the body does not use insulin properly, causing blood sugar levels to become too high.
This study is seeking participants in Japan who:
* Have obesity disease. * May have type 2 diabetes. * Meet the study-specific age, weight and health requirements.
About 180 adults will take part in this study. Participants will be randomly assigned to receive either berobenatide or a placebo. A placebo looks like the study medicine but does not contain any active medicine.
Berobenatide or placebo will be given as an injection under the skin of the abdomen (belly area). The study will compare the experiences of people receiving berobenatide with those receiving placebo to determine whether berobenatide can help people lose weight. The study will also assess the safety of berobenatide and its effects on body weight and other health measures.
People will take part in this study for about 22 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.
Inclusion: Aged ≥18 years; BMI of: ≥27.0 kg/m2 to <35.0 kg/m2 with ≥2 obesity-related health disorders or BMI of ≥35.0 kg/m2 with ≥1 obesity-related health disorder. The participant must have at least one of either hypertension, dyslipidemia or glucose intolerance (T2D and impaired glucose tolerance etc.) as an obesity-related health disorder.
Exclusion: Have a self-reported body weight change greater than 5% within 90 days prior to Screening; Diagnosis of type 1 diabetes or any other form of diabetes other than T2D; History of acute or chronic pancreatitis; Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).